Titan Biotech Limited (BOM:524717)
India
· Delayed Price · Currency is INR 422.85
-3.20 (-0.75%)
At close: Jun 17, 2025
Titan Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 1,565 | 1,641 | 1,440 | 1,235 | 1,422 | Upgrade
|
| Other Revenue | - | - | - | - | 0.04 | Upgrade
|
| Revenue | 1,565 | 1,641 | 1,440 | 1,235 | 1,422 | Upgrade
|
| Revenue Growth (YoY) | -4.64% | 13.94% | 16.55% | -13.14% | 79.05% | Upgrade
|
| Cost of Revenue | 726.28 | 769.36 | 710.43 | 598.28 | 645.68 | Upgrade
|
| Gross Profit | 838.23 | 871.36 | 729.57 | 637.21 | 776.72 | Upgrade
|
| Selling, General & Admin | 263.8 | 267.96 | 209.68 | 148.78 | 144.39 | Upgrade
|
| Other Operating Expenses | 320.17 | 262.02 | 225.04 | 176.6 | 166.14 | Upgrade
|
| Operating Expenses | 625.66 | 563.29 | 461.52 | 349.08 | 334.8 | Upgrade
|
| Operating Income | 212.57 | 308.08 | 268.05 | 288.13 | 441.92 | Upgrade
|
| Interest Expense | -8.02 | -7.96 | -4.5 | -5.99 | -14.79 | Upgrade
|
| Interest & Investment Income | - | 0.86 | 0.44 | 1.13 | 0.57 | Upgrade
|
| Earnings From Equity Investments | 32.61 | 11.9 | 38.19 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 6.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 39.13 | 8.69 | 16.68 | 6.44 | -1.49 | Upgrade
|
| EBT Excluding Unusual Items | 276.28 | 321.56 | 318.87 | 289.71 | 432.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 5.63 | 0.49 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.02 | -0.03 | Upgrade
|
| Asset Writedown | - | - | - | - | -1.88 | Upgrade
|
| Other Unusual Items | - | - | - | - | -3.24 | Upgrade
|
| Pretax Income | 276.28 | 327.19 | 319.35 | 289.69 | 427.06 | Upgrade
|
| Income Tax Expense | 60.96 | 78.66 | 70.91 | 72.85 | 110 | Upgrade
|
| Earnings From Continuing Operations | 215.32 | 248.53 | 248.44 | 216.84 | 317.05 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -13.7 | Upgrade
|
| Net Income | 215.32 | 248.53 | 248.44 | 216.84 | 303.35 | Upgrade
|
| Net Income to Common | 215.32 | 248.53 | 248.44 | 216.84 | 303.35 | Upgrade
|
| Net Income Growth | -13.36% | 0.03% | 14.57% | -28.52% | 329.33% | Upgrade
|
| Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | -0.02% | - | - | - | - | Upgrade
|
| EPS (Basic) | 26.06 | 30.07 | 30.06 | 26.24 | 36.71 | Upgrade
|
| EPS (Diluted) | 26.06 | 30.07 | 30.06 | 26.24 | 36.71 | Upgrade
|
| EPS Growth | -13.35% | 0.03% | 14.57% | -28.52% | 329.35% | Upgrade
|
| Free Cash Flow | 107.55 | 16.61 | 84.45 | 157.29 | 160.71 | Upgrade
|
| Free Cash Flow Per Share | 13.02 | 2.01 | 10.22 | 19.03 | 19.45 | Upgrade
|
| Dividend Per Share | 2.000 | 2.000 | 1.800 | 1.500 | 1.500 | Upgrade
|
| Dividend Growth | - | 11.11% | 20.00% | - | 50.00% | Upgrade
|
| Gross Margin | 53.58% | 53.11% | 50.66% | 51.58% | 54.61% | Upgrade
|
| Operating Margin | 13.59% | 18.78% | 18.62% | 23.32% | 31.07% | Upgrade
|
| Profit Margin | 13.76% | 15.15% | 17.25% | 17.55% | 21.33% | Upgrade
|
| Free Cash Flow Margin | 6.87% | 1.01% | 5.86% | 12.73% | 11.30% | Upgrade
|
| EBITDA | 254.26 | 336.52 | 289.21 | 307.71 | 460.33 | Upgrade
|
| EBITDA Margin | 16.25% | 20.51% | 20.08% | 24.91% | 32.36% | Upgrade
|
| D&A For EBITDA | 41.7 | 28.44 | 21.16 | 19.58 | 18.41 | Upgrade
|
| EBIT | 212.57 | 308.08 | 268.05 | 288.13 | 441.92 | Upgrade
|
| EBIT Margin | 13.59% | 18.78% | 18.62% | 23.32% | 31.07% | Upgrade
|
| Effective Tax Rate | 22.07% | 24.04% | 22.20% | 25.15% | 25.76% | Upgrade
|
| Revenue as Reported | - | 1,658 | 1,459 | 1,245 | 1,430 | Upgrade
|
| Advertising Expenses | - | 26.12 | 26.42 | 5.48 | 2.51 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.